In conclusion, the use of 68Ga-FAPI PET/CT showed promising results to improve diagnosis and (re)staging of PDAC, and might in the future be combined with FAP-targeted therapies (e.g., radionuclide therapy), which has already been evaluated in the preclinical setting by Lui et al., demonstrating a significant tumor suppressing effect using 177Lu-FAPI-46 and 225Ac-FAPI-46 in PANC-1 xenograft mouse models. Here, FAP is linked to neoplasm.